Related Experiment Video
Updated: Dec 20, 2025
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
Advances in drug development for targeted therapies for glioblastoma
Ge Yan1,2, Yunfu Wang2, Jincao Chen1
1Department of Neurosurgery, School of Pharmaceutical Sciences, Zhongnan Hospital, Wuhan University, Wuhan, Hubei, China.
Abstract:
Glioblastoma is the most aggressive primary brain tumor in adults. The prognosis of patients with primary glioblastoma treated with the current standard of care, tumor resection followed by radiation therapy and auxiliary temozolomide, remains poor. Integrative genomic analyses have identified essential core signaling pathways and frequent genetic aberrations, which provide potential drug targets for glioblastoma treatment. Drugs against these therapeutic targets have been developed rapidly in recent years. Although some have shown promising effects on models in preclinical studies, many have shown only modest efficacy in clinical trials. New therapeutic strategies and potent drugs are urgently needed to improve the prognosis of patients with glioblastoma. The goal of this review is to summarize the current advances in drug development for targeted glioblastoma therapies and to reveal the major challenges encountered in clinical trials or treatment. This study will provide new perspectives for future studies of targeted therapeutic drug development and provide insights into the clinical treatment of glioblastoma.
Insights
Glioblastoma treatment faces challenges despite targeted drug development. New strategies are crucial for improving patient outcomes in this aggressive brain cancer.
Area of Science:
- Neuro-oncology
- Cancer Pharmacology
- Genomics
Background:
- Glioblastoma is an aggressive brain tumor with a poor prognosis despite standard treatments like surgery, radiation, and temozolomide.
- Integrative genomic analyses reveal key signaling pathways and genetic alterations in glioblastoma, offering potential drug targets.
Purpose of the Study:
- To review recent advancements in targeted drug development for glioblastoma.
- To identify challenges in clinical trials and treatment of glioblastoma.
- To offer new perspectives for future targeted therapy research and clinical application.
Main Methods:
- Literature review of preclinical and clinical studies on targeted glioblastoma therapies.
- Analysis of genomic data to identify drug targets.
- Synthesis of information on drug efficacy and clinical trial outcomes.
Main Results:
- Numerous targeted drugs have been developed, showing promise in preclinical models.
- Many targeted therapies exhibit limited efficacy in clinical trials, highlighting treatment challenges.
- Urgent need for novel therapeutic strategies and more potent drugs for glioblastoma.
Conclusions:
- Targeted therapies for glioblastoma have advanced, but clinical success remains limited.
- Overcoming challenges in clinical trials is essential for effective glioblastoma treatment.
- Future research should focus on developing more potent drugs and innovative therapeutic approaches.
More Related Videos
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
07:25Author Spotlight: Multimodal Imaging Strategies for Optimizing Drug Delivery and Early Detection in Glioblastoma Treatment
Published on: March 1, 2024
